HealthQuill Cancer
IntraBio Inc, a biotechnology company focused on rare and neurodegenerative diseases, got the US regulator’s nod for a drug to treat a certain type of Niemann-Pick disease in adults and pediatric patients weighing about 15 kilograms.
Health

Primary care clinics can help detect 10% of cancers caused by genes

HQ Team March 10, 2025: Patient screening in primary care settings can detect up to 10% of cancers caused by genes. Easily available.

Read More
US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice, pointing to a new potential target for cancer treatment, according to the National Institutes of Health.
Drugs Health Research

US scientists block proteins that aid cancer cells’ group strategy to survive

HQ Team March 5, 2025: US scientists have blocked a protein that kills a variety of cancer cells in an experiment on mice,.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous chemotherapy.
Health Medical Pharma

South Korea’s Hyundai ADM unveils oral chemotherapy drug

Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Drugs Medical Pharma

AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients

The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.

Read More
Abnormal prenatal blood results are indicative of hidden cancers in pregnant women, researchers at the US nation’s medical research agency, the National Institutes of Health, found.
Health Medical Pharma Research

Prenatal blood tests may reveal hidden cancers in pregnant women: NIH

Abnormal prenatal blood results are indicative of hidden cancers in pregnant women, researchers at the US nation’s medical research agency, the National Institutes.

Read More
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the French company will invest 300 million euros for a 16% equity.
Drugs Health Pharma

Sanofi to invest $324m in entity with Orano Med for radioligand therapy

Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.

Read More